MCID: INF009
MIFTS: 31

Inflammatory Spondylopathy

Categories: Bone diseases

Aliases & Classifications for Inflammatory Spondylopathy

MalaCards integrated aliases for Inflammatory Spondylopathy:

Name: Inflammatory Spondylopathy 12 15
Inflammatory Spondylopathies in Disease Classified Elsewhere 12
Inflammatory Spondylopathy in Disease Classified Elsewhere 12
Inflammatory Spondylopathies in Disease Ec 12
Spondylitis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12105
ICD9CM 34 720.81
ICD10 32 M46.8 M46.9
UMLS 71 C0021396 C0038012

Summaries for Inflammatory Spondylopathy

MalaCards based summary : Inflammatory Spondylopathy, also known as inflammatory spondylopathies in disease classified elsewhere, is related to discitis and spondylitis, and has symptoms including sciatica An important gene associated with Inflammatory Spondylopathy is LINC00523 (Long Intergenic Non-Protein Coding RNA 523). The drugs Indomethacin and Loxoprofen have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes.

Related Diseases for Inflammatory Spondylopathy

Diseases related to Inflammatory Spondylopathy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 discitis 10.4
2 spondylitis 10.4

Symptoms & Phenotypes for Inflammatory Spondylopathy

UMLS symptoms related to Inflammatory Spondylopathy:


sciatica

Drugs & Therapeutics for Inflammatory Spondylopathy

Drugs for Inflammatory Spondylopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
2
Loxoprofen Approved Phase 4 68767-14-6, 80382-23-6 3965
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Aceclofenac Approved, Investigational Phase 4 89796-99-6
5
Pamidronate Approved Phase 4 40391-99-9 4674
6
carbamide peroxide Approved Phase 4 124-43-6
7
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13 Natriuretic Peptide, Brain Phase 4
14 Tocolytic Agents Phase 4
15 Tripterygium Phase 4
16 Mitogens Phase 4
17 Endothelial Growth Factors Phase 4
18 Cholestyramine Resin Phase 4
19 Antibodies, Monoclonal Phase 4
20 Cyclooxygenase 2 Inhibitors Phase 4
21 Antiprotozoal Agents Phase 4
22 Antiparasitic Agents Phase 4
23 Antimalarials Phase 4
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Analgesics Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Narcotics Phase 4
29 Antipyretics Phase 4
30 Analgesics, Opioid Phase 4
31
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
32
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
33
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
34 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
35
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
36
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
37
Certolizumab pegol Approved Phase 3 428863-50-7
38
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
39
Misoprostol Approved Phase 3 59122-46-2 5282381
40
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
41 Brodalumab Approved, Investigational Phase 3 1174395-19-7
42
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
43
Tofacitinib Approved, Investigational Phase 2, Phase 3 477600-75-2
44
Upadacitinib Approved, Investigational Phase 3 1310726-60-3 58557659
45
tannic acid Approved Phase 3 1401-55-4
46
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
47
Ustekinumab Approved, Investigational Phase 3 815610-63-0
48
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
49
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
50
Rebamipide Investigational Phase 3 90098-04-7

Interventional clinical trials:

(show top 50) (show all 446)
# Name Status NCT ID Phase Drugs
1 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Unknown status NCT02492217 Phase 4 Adalimumab
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
4 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
5 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
6 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
7 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
8 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
9 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
10 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
11 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
12 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
13 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
14 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
15 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
16 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
17 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
18 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
19 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
20 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
21 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
22 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
23 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
24 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
25 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
26 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
27 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
28 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
29 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
30 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Completed NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
31 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
32 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
33 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
34 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
35 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
36 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab
37 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
38 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
39 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
40 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
41 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
42 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
43 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
44 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Recruiting NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
45 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
46 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
47 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Recruiting NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
48 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Recruiting NCT02687724 Phase 4 Golimumab (GLM)
49 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Active, not recruiting NCT02758782 Phase 4 Celecoxib
50 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)

Search NIH Clinical Center for Inflammatory Spondylopathy

Genetic Tests for Inflammatory Spondylopathy

Anatomical Context for Inflammatory Spondylopathy

MalaCards organs/tissues related to Inflammatory Spondylopathy:

40
Bone, T Cells, Testes, Spinal Cord, Lung, Endothelial, Heart

Publications for Inflammatory Spondylopathy

Articles related to Inflammatory Spondylopathy:

(show top 50) (show all 16554)
# Title Authors PMID Year
1
A rare case of disseminated tuberculosis; multiple intracranial and intramedullary tuberculomas with concurrent tuberculous spondylitis and meningitis. 61
32548312 2020
2
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. 61
32381562 2020
3
Notch receptors and ligands in inflammatory arthritis - a systematic review. 61
32325090 2020
4
Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? 61
32327428 2020
5
Tuberculous spondylitis following intravesical bcg-instillation in the treatment of transitional cell carcinoma: Case report and systematic review. 61
32480296 2020
6
How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula. 61
31628804 2020
7
Spondyloarthritis evolution: what is in your history? 61
32453039 2020
8
Familial aggregation and heritability of ankylosing spondylitis - a Swedish nested case-control study. 61
31687771 2020
9
Ochronosis of the spine mimicking ankylosing spondylitis successfully treated with anakinra. 61
32147566 2020
10
Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. 61
32166439 2020
11
Combined percutaneous and open instrumentation for thoracolumbar kyphosis correction by two-level pedicle subtraction osteotomy in ankylosing spondylitis. 61
31980911 2020
12
Endoplasmic reticulum aminopeptidase 2 gene single nucleotide polymorphisms in association with susceptibility to ankylosing spondylitis in an Iranian population. 61
32360304 2020
13
Correction: "Changes in the medical burden of pyogenic and tuberculous spondylitis between 2007 and 2016: A nationwide cohort study". 61
32499205 2020
14
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. 61
32157555 2020
15
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. 61
30900514 2020
16
Mud-bath treatment of seronegative spondyloarthritis: experience at the Euganean Thermal Area. 61
31342241 2020
17
Rheumatologic Disorders and the Nervous System. 61
32487898 2020
18
Oral health-related quality of life in different rheumatic diseases. 61
32510714 2020
19
Spondyloarthritis-Associated IgA Nephropathy. 61
32518863 2020
20
Risk of incident autoimmune diseases in patients with thymectomy. 61
32478484 2020
21
Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. 61
32492107 2020
22
Predictive Utility of Cardiovascular Risk Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review. 61
31416923 2020
23
The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review. 61
32270447 2020
24
Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases. 61
32361936 2020
25
Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas: a mixed-methods study within a national register. 61
32522742 2020
26
Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. 61
32539800 2020
27
Fertility and sexuality of women with inflammatory arthritis. 61
32540625 2020
28
Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort. 61
32562362 2020
29
An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. 61
31852583 2020
30
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. 61
32529495 2020
31
Cervical Abnormalities in Severe Spinal Deformity: A 10-year MRI Review. 61
32351029 2020
32
Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. 61
32533340 2020
33
Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study. 61
32062827 2020
34
The comparison analysis of clinical and radiological features in SAPHO syndrome. 61
32504191 2020
35
Rheumatological conditions as risk factors for self-harm: A retrospective cohort study. 61
32526099 2020
36
Pentraxin 3: A promising therapeutic target for autoimmune diseases. 61
32534154 2020
37
Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines. 61
32444009 2020
38
Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. 61
32567403 2020
39
B7-H3: A promising therapeutic target for autoimmune diseases. 61
32113615 2020
40
Brucellosis spondylitis. 61
32251793 2020
41
Tuberculosis of the axial skeleton mimicking malignancy. 61
32568293 2020
42
Biologics, spondylitis and COVID-19. 61
32522741 2020
43
Anterior oblique retroperitoneal approach vs posterior transpedicular approach for the treatment of one- or two-level lumbar vertebral osteomyelitis: a retrospective cohort study. 61
32500308 2020
44
Spa therapy and rehabilitation of musculoskeletal pathologies: a proposal for best practice in Italy. 61
31129759 2020
45
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. 61
31615919 2020
46
Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome. 61
32455150 2020
47
Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. 61
31785165 2020
48
Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. 61
31858121 2020
49
[Radiological diagnostics of lumbar spine fractures]. 61
32561936 2020
50
Is There a Brain/Heart Interaction in Rheumatoid Arthritis and Seronegative Spondyloartropathies? A Combined Brain/Heart Magnetic Resonance Imaging Reveals the Answer. 61
32562092 2020

Variations for Inflammatory Spondylopathy

Expression for Inflammatory Spondylopathy

Search GEO for disease gene expression data for Inflammatory Spondylopathy.

Pathways for Inflammatory Spondylopathy

GO Terms for Inflammatory Spondylopathy

Sources for Inflammatory Spondylopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....